Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996

Journal of Rheumatology

Volumn 25, Issue 3, 1998, Pages 408-416

  Ward, Michael M ^a,c   Fries, James F ^b  

^a Rheumatology Section

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Disease modifying antirheumatic drugs; Nonsteroidal antiinlammatory drugs; Prednisone; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN A; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; GOLD; HYDROXYCHLOROQUINE; IBUPROFEN; KETOPROFEN; MAGNESIUM SILICATE; MECLOFENAMIC ACID; METHOTREXATE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PENICILLAMINE; PIROXICAM; PREDNISONE; SALAZOSULFAPYRIDINE; SALSALATE; SULINDAC; TOLMETIN; UNINDEXED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; DRUG USE; FEMALE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STEROID THERAPY;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREDNISONE;

EID: 0031934699     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wilske K, Healey L. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
2. Bensen WG, Adachi JD, Tugwell PX. Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 1990; 17:987-9.
3. McCarty DJ. Suppress rheumatoid arthritis early and leave the pyramid to the Egyptians. J Rheumatol 1990;17:1115-8.
4. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
5. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36:297-306.
6. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
7. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989;79 Suppl:67-95.
8. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcomes of treating rheumatoid arthritis: Results after 20 years. Lancet 1987;1:1108-11.
9. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
10. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
11. Sibley JT, Haga LM. Outcome of rheumatoid arthritis followed over 30 years [abstract]. Arthritis Rheum 1996;39 Suppl: S156.
12. Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. Arch Intern Med 1993;153:2229-37.
13. Ropes NW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
14. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994;37:1487-91.
15. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
16. O'Dell JR, Haire CE, Eriksons N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
17. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33:1611-9.
18. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:20-5.
19. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
20. Suarez-Almazor ME, Soskolne CL, Saunders D, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
21. Owen SG, Friesen WT, Roberts MS, Francis H, Flux W. Functional capacity and treatment data from a community based study of patients with rheumatoid arthritis. Ann Rheum Dis 1986; 45:293-303.
22. Friesen WT, Hekster YA, van de Putte LBA, Gribnau FWJ. Cross-sectional study of rheumatoid arthritis treatment in a university hospital. Ann Rheum Dis 1985;44:372-8.
23. Byron MA, Mowat AG. Corticosteroid prescribing in rheumatoid arthritis - the fiction and the fact. Br J Rheumatol 1985; 24:164-6.
24. Gibson T, Clark B. Use of simple analgesics in rheumatoid arthritis. Ann Rheum Dis 1985;44:27-9.
25. Pincus T, Callahan LF. Clinical use of multiple nonsteroidal antiinflammatory drug preparations within individual rheumatology practices. J Rheumatol 1989;16:1253-8.
26. Pincus T, Marcum SB, Callahan LF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992; 19:1874-84.
27. Hakala M, Nieminen P, Koivisto O. More evidence from a community based series of better outcome in rheumatoid arthritis. Data on the effect of multidisciplinary care on the retention of functional ability. J Rheumatol 1994;21:1432-7.
28. Porter DR, McInnes I, Hunter J, Capell HA. Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis 1994; 53:812-5.
29. Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum 1996; 39:996-1005.